detection of preclinical alzheimer’s diseas for the ... · center for development of advanced...

16
National Center for Geriatrics and Gerontology Center for Development of Advanced Medicine for Dementia Katsuhiko Yanagisawa Detection of preclinical Alzheimer’s diseas for the preemptive therapy

Upload: others

Post on 04-Feb-2021

5 views

Category:

Documents


0 download

TRANSCRIPT

  • National Center for Geriatrics and GerontologyCenter for Development of Advanced Medicine for Dementia

    Katsuhiko Yanagisawa

    Detection of preclinical Alzheimer’s diseasfor the preemptive therapy

  • Stop Alzheimer Disease Before It Starts !

    Greg Miller, Science 337, 790-792, 2012

  • Mangialasche et al., Lancet Neurology, 9:702-716, 2010

  • Illustration by Gracia Lam

    A tangled web of targetsDrugs in development for Alzheimer's disease take aim at a variety of neural mechanisms.But despite a wealth of possibilities, there have been few successes. Lauren Gravitz

    Nature 475, S9, 2011

  • too late for therapeutic intervention

  • Bateman et al, New Engl J Med, 367: 795-804, 2012

    Carriers

    Noncarriers

    Estimated Yr fromSymptom Onset -20 -10 0

    PiB-amyloid imaging on PET- Study on familial Alzheimer disease -

  • clinical threshold

    time

    degr

    ee

    preclinicalAD

    MCI AD muc

    h co

    gniti

    ve re

    serv

    ele

    ss c

    ogni

    tive

    rese

    rve

    synapse loss

    neuron loss

    tangle formation

    inflammation etc

    Yanagisawa, Cognition and Dementia, 2012

  • amyloid-dependent phase

    amyloid-independent phase

    Alzheimer Disease

    ・inflammation・oxidative stress

    ・mitochondria injuryetc

    ・impairment of calcium homeostasis・energy failureetc

    ・disruption of neuronal network

    switch

    modified from Yanagisawa. Igaku-no-Ayumi 239: 379-382, 2011

  • amyloid-dependent phase

    amyloid-independent phase

    Alzheimer Disease

    ・inflammation・oxidative stress

    ・mitochondria injuryetc

    ・impairment of calcium homeostasis・energy failureetc

    ・disruption of neuronal network

    anti-amyloid therapy

    effective ineffective

    switch

  • Pathological stage of Alzheimer Disease

    Modified Jack et al. The Lancet Neurology, 2010

    previous and current clinical trials

    preemptive therapysecondary prevention

  • Alzheimer Disease

    How should you know the pathological change before clinical onset?

  • Cerebrospinal fluid examination

    (Yahoo Japanより取得)

  • Amyloid imaging on PET

  • Plasma!

    obtained from Yahoo Japan

  • Rembach A et al., Alzheimer’s and Dementia,10: 53-61, 2014

    Plasma amyloid ß-proteins Baseline

    18-months later

  • **

    * **

    * * * * **

    *

    ** * **

    * * * *Aβ

    [1-4

    0]3000 3500 4000 4500 5000 5500m/z

    x5 x5

    n

    n

    nn

    n

    n nn n

    0

    20

    40

    60

    80

    100

    *various Aßs and Aß-approximate peptides

    Aβ[1

    -42]

    *

    Novel procedure to detect Aß from plasma usingmass spectrometry

    Kaneko et al., Proc. Jpn. Acad. Ser. B,104-117, 2014

    スライド番号 1スライド番号 2スライド番号 3スライド番号 4スライド番号 5スライド番号 6スライド番号 7スライド番号 8スライド番号 9スライド番号 10スライド番号 11スライド番号 12スライド番号 13スライド番号 14スライド番号 15スライド番号 16